ArticleJournal of nanobiotechnology2025
Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthesis, characterisation, andFrontiers in drug delivery · 2026Article
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
- EngineeringExtracellular vesicles and circulating nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the current era of the global increase in autoimmune and inflammatory disorders, predominantly rheumatoid arthritis (RA), there is mounting interest in developing advanced, safe, and patient-compliant treatment strategies. Phytoconstituents have gained more attention in recent years as budding complementary medicines for RA. Among them, 3-Acetyl-11-keto-β-boswellic acid (AKBA), derived from Boswellia serrata extract, is considered a promising phytoconstituent due to its anti-inflammatory and anti-arthritic potential. However, due to its poor solubility, low bioavailability (less than 10%), and poor permeability, its therapeutic potential is limited. Therefore, to overcome these issues, we have developed novel hyaluronic acid-surface-engineered lyotropic liquid crystalline nanoparticles encapsulating AKBA (HA-AKBA-LCNP) for cutaneous site-specific distribution and enhanced therapeutic effectiveness in RA.
resultsThe quality-by-design-based optimized uncoated LCNP (N-AKBA-LCNP) and HA-AKBA-LCNP exhibited particle sizes below 150 nm and entrapment efficiency (%) close to 80%, making them suitable for cutaneous penetration and availability at the disease site. The cell viability studies in the RAW264.7 cell line revealed no cytotoxicity. Uncoated LCNP and HA-coated LCNP showed 1.37- and 2.19-fold improved cell uptake, respectively, compared to free form. An in vitro study also demonstrated a significant anti-inflammatory effect of the developed LCNP system against RAW264.7 cells, characterized by a decrease in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines. The N-AKBA-LCNP and HA-AKBA-LCNP embedded gels demonstrated improved permeation (2.34- and 2.40-fold, respectively) and improved retention (4.98- and 6.73-fold, respectively) of AKBA in the viable dermal layers compared to the free AKBA gel. In vivo investigation revealed a significant depletion in paw edema (p < 0.0001), inflammatory cytokine levels (p < 0.0001), and CD44 expression (p < 0.001) by HA-AKBA-LCNP in the Freund's Complete Adjuvant-induced rat model of arthritis.
conclusionThe study results exhibited the promising potential of HA-functionalized AKBA-loaded LCNP as a targeted, biocompatible, and efficient dermal delivery approach for an enhanced treatment strategy to counter the RA disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.